Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Nosaka, Kazumasa, Tsushima, Ryu, Ugawa, Satoko, Takagi, Wataru, Sogo, Masahiro, Takahashi, Masahiko, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144976/
https://www.ncbi.nlm.nih.gov/pubmed/35621864
http://dx.doi.org/10.3390/jcdd9050153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144976/
https://www.ncbi.nlm.nih.gov/pubmed/35621864
http://dx.doi.org/10.3390/jcdd9050153

Ejemplares similares